$FATE (2/3)

-Initiated P1 study of FT538 (first CRISPR-edited iPSC)

-Pulled off upsized secondary offering, $JNJ bought more (also disclosed responder to low dose FT596, had 4 prior lines of therapy)

-And now next gen CD19-targeting CAR-T FT819 moves into phase 1 study  👍